This result indicated that the current signature might be taken as an alternative signature to predict the response to ICIs, which was confirmed by the IMvgior 210 cohort, which consisted of 298 urothelial carcinoma patients receiving atezolizumab (a PD-L1 inhibitor). The gene discussed is CD274; the disease is urothelial carcinoma.